Remacemide
Chemical compound / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Remacemide?
Summarize this article for a 10 year old
Remacemide is a drug which acts as a low-affinity NMDA antagonist with sodium channel blocking properties.[2] It has been studied for the treatment of acute ischemic stroke,[3][4] epilepsy,[5] Huntington's disease, and Parkinson's disease.
Clinical data | |
---|---|
Trade names | Ecovia[1] |
Other names | (±)-2-amino-N-[1,2-di(phenyl)propan-2-yl]acetamide PR 934-423 |
Routes of administration | By mouth |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider |
|
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C17H20N2O |
Molar mass | 268.360 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
Because remacemide has only a modest effect on seizure frequency and causes dizziness, it is no longer believed that remacemide will be an effective treatment for epilepsy.[6] Although no such statement has been made about remacemide's potential for treating stroke, Huntington's, or Parkinson's, remacemide is no longer being developed for these conditions.[citation needed]
Remacemide is also known as remacemide hydrochloride, (±)-2-amino-N-(1-methyl-1,2-diphenylethyl)-acetamide hydrochloride, or FPL 12924AA.[7]